IMBRUVICA (ibrutinib) Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Shows Superior Progression-Free Survival Compared to Chlorambucil Plus Obinutuzumab in First-line Chronic Lymphocytic Leukemia (CLL) Phase 3 GLOW Study